Join us in congratulating Dr. Amitabha Mazumder
Join us in congratulating TOI physician Dr. Amitabha Mazumder on his latest publication in the American Society of Clinical Oncology (ASCO)’s Journal of Clinical Oncology!
Melphalan flufenamide (melflufen) is a first-in-class peptide-drug that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of melflufen plus dexamethasone in relapsed and refractory multiple myeloma (RRMM), a population with an important unmet medical need.
Thank you, Dr. Mazumder, for your ongoing commitment to research in the field of oncology. You can read a digital version of the publication here.
